468 related articles for article (PubMed ID: 19307506)
1. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
5. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
8. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
10. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Ståhl O; Cavallin-Ståhl EK; Klepp OH; Dahl O; Cohn-Cedermark G
J Clin Oncol; 2011 Feb; 29(6):719-25. PubMed ID: 21205748
[TBL] [Abstract][Full Text] [Related]
11. [BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors].
Mori Y; Shima H; Ihara H; Yabumoto H; Iwasaki A; Yoshioka M; Ikoma F
Hinyokika Kiyo; 1992 Oct; 38(10):1139-42. PubMed ID: 1282774
[TBL] [Abstract][Full Text] [Related]
12. Is bleomycin necessary in adjuvant chemotherapy of clinical stage I non-seminomatous testicular cancer?
Mezvrishvili Z; Managadze L
Georgian Med News; 2006 May; (134):25-8. PubMed ID: 16783058
[TBL] [Abstract][Full Text] [Related]
13. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
14. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.
Cohn-Cedermark G; Stahl O; Tandstad T;
Andrology; 2015 Jan; 3(1):102-10. PubMed ID: 25270123
[TBL] [Abstract][Full Text] [Related]
15. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
[TBL] [Abstract][Full Text] [Related]
16. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy.
Gilbert DC; Norman AR; Nicholl J; Dearnaley DP; Horwich A; Huddart RA
BJU Int; 2006 Jul; 98(1):67-9. PubMed ID: 16831145
[TBL] [Abstract][Full Text] [Related]
17. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
20. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
